Epitope Mapping of Anti-Interleukin-13 Neutralizing Antibody CNTO607

Journal of Molecular Biology

Volumn 389, Issue 1, 2009, Pages 115-123

  Teplyakov, Alexey ^a   Obmolova, Galina ^a   Wu, Sheng Jiun ^a   Luo, Jinquan ^a   Kang, James ^a   O'Neil, Karyn ^a   Gilliland, Gary L ^a  

^a CENTOCOR INC   (United States)

Author keywords

antibody; crystal structure; cytokine; epitope; mutagenesis

Indexed keywords

ALANINE; ASPARTIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO607; NEUTRALIZING ANTIBODY; PHENYLALANINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEMENTARITY DETERMINING REGION; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; ELECTRICITY; EPITOPE MAPPING; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR BINDING; WASTE; X RAY CRYSTALLOGRAPHY;

EID: 67349146355     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.03.076     Document Type: Article

References (27)

1. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202 (2004) 175-190
2. Heinzmann A., Mao X.Q., Akaiwa M., Kreomer R.T., Gao P.S., Ohshima K., et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum. Mol. Genet. 9 (2000) 549-559
3. Huang S.K., Xiao H.Q., Kleine-Tebbe J., Paciotti G., Marsh D.G., Lichtenstein L.M., and Liu M.C. IL-13 expression at the sites of allergen challenge in patients with asthma. J. Immunol. 155 (1995) 2688-2694
4. Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103 (1999) 779-788
5. Therien A.G., Bernier V., Weicker S., Tawa P., Falgueyret J.P., Mathieu M.C., et al. Adenovirus IL-13-induced airway disease in mice. Am. J. Respir. Cell Mol. Biol. 39 (2008) 26-35
6. Grunig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998) 2261-2263
7. Blease K., Jakubzick C., Westwick J., Lukacs N., Kunkel S.L., and Hogaboam C.M. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J. Immunol. 166 (2001) 5219-5224
8. Yang G., Volk A., Petley T., Emmell E., Giles-Komar J., Shang X., et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28 (2004) 224-232
9. Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J., et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J. Pharmacol. Exp. Ther. 313 (2005) 8-15
10. Kasaian M.T., Tan X.Y., Jin M., Fitz L., Marquette K., Wood N., et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 325 (2008) 882-892
11. Krause S., Behrends J., Borowski A., Lohrmann J., Lang S., Myrtek D., et al. Blockade of interleukin-13-mediated cell activation by a novel inhibitory antibody to human IL-13 receptor alpha1. Mol. Immunol. 43 (2006) 1799-1807
12. Thom G., Cockroft A.C., Buchanan A.G., Candotti C.J., Cohen E.S., Lowne D., et al. Probing a protein-protein interaction by in vitro evolution. Proc. Natl. Acad. Sci. USA 103 (2006) 7619-7624
13. Vugmeyster Y., Szklut P., Tchistiakova L., Abraham W., Kasaian M., and Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int. Immunopharmacol. 8 (2008) 477-483
14. Aman M.G., Tayebi N., Obiri N.I., Puri R.K., Modi W.S., and Leonard W.J. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J. Biol. Chem. 271 (1996) 29265-29270
15. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., and Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12 (2006) 99-106
16. Rothe C., Urlinger S., Loehning C., Prassler J., Stark Y., Jaeger U., et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J. Mol. Biol. 376 (2008) 1182-1200
17. Eisenmesser E.Z., Horita D.A., Altieri A.S., and Byrd R.A. Solution structure of interleukin-13 and insights into receptor engagement. J. Mol. Biol. 310 (2001) 231-241
18. Moy F.J., Diblasio E., Wilhelm J., and Powers R. Solution structure of human IL-13 and implication for receptor binding. J. Mol. Biol. 310 (2001) 219-230
19. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132 (2008) 259-272
20. Chen J., Blackford Jr. J.A., and Simons Jr. S.S. PCR expression mutagenesis: a high-throughput mutation assay applied to the glucocorticoid receptor ligand-binding domain. Biochem. Biophys. Res. Commun. 321 (2004) 893-899
21. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
22. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr., Sect. D: Biol. Crystallogr. 57 (2001) 1373-1382
23. Hulsmeyer M., Chames P., Hillig R.C., Stanfield R.L., Held G., Coulie P.G., et al. A major histocompatibility complex-peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3. J. Biol. Chem. 280 (2005) 2972-2980
24. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
25. Collaborative Computational Project No. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1994) 240-255
26. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132
27. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, San Carlos, CA